Ameriprise Financial Inc. Buys 23,007 Shares of Moderna, Inc. (NASDAQ:MRNA)

Ameriprise Financial Inc. lifted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 10.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,280 shares of the company's stock after acquiring an additional 23,007 shares during the quarter. Ameriprise Financial Inc. owned 0.06% of Moderna worth $9,784,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Allworth Financial LP grew its position in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after purchasing an additional 281 shares during the period. Howard Capital Management Inc. boosted its stake in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after buying an additional 297 shares during the last quarter. Itau Unibanco Holding S.A. grew its holdings in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the period. Commonwealth Equity Services LLC increased its position in Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after acquiring an additional 345 shares during the last quarter. Finally, Larson Financial Group LLC lifted its holdings in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after acquiring an additional 356 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on MRNA shares. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Barclays reduced their target price on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. UBS Group reduced their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $53.95.

Moderna Stock Up 6.2%

Moderna stock opened at $26.39 on Tuesday. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47. The firm's fifty day moving average is $27.70 and its 200 day moving average is $35.11. The company has a market cap of $10.21 billion, a price-to-earnings ratio of -2.84 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same quarter last year, the firm earned ($3.07) EPS. The firm's revenue for the quarter was down 35.3% compared to the same quarter last year. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.